| Market Capitalization (Millions $) |
878 |
| Shares
Outstanding (Millions) |
201 |
| Employees |
96 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-203 |
| Cash Flow (TTM) (Millions $) |
43 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Annexon Inc is a biopharmaceutical company that is focused on developing therapies for patients with autoimmune and neurodegenerative diseases. The company was founded in 2011 in South San Francisco, California, and has since expanded operations and staff to multiple locations, including Brisbane, California, and New Haven, Connecticut.
The company's research efforts are centered around a unique approach to treating autoimmune and neurodegenerative disorders by targeting the complement pathway, which is a key part of the immune system that plays a critical role in fighting infections and maintaining tissue homeostasis. Dysregulation of the complement pathway has been linked to a variety of diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. Annexon's focus is on developing therapies that carefully modulate this pathway to restore balance and halt disease progression.
One of the company's most promising drug candidates is ANX005, which is being developed for the treatment of complement-mediated autoimmune and neurodegenerative diseases. ANX005 is designed to specifically target the C1q protein, which is a key regulator of the complement pathway.
Annexon has received significant funding from both venture capital firms and pharmaceutical companies. The company raised $75 million in a Series C funding round in 2020 and has secured partnerships with several top-tier companies in the biopharmaceutical industry, including Biogen and Takeda.
The company's leadership team includes a number of industry veterans with extensive experience in drug development and biotechnology. CEO Doug Love was formerly the COO of Rigel Pharmaceuticals, while Chief Scientific Officer Ben Barres was a renowned neuroscientist and professor at Stanford University prior to joining Annexon.
Overall, Annexon Inc is a fast-growing biopharmaceutical company with a promising pipeline of drug candidates and a unique approach to treating complex diseases. With strong funding, partnerships, and leadership, the company is well positioned to continue making significant contributions to the field of medicine.
Company Address: 1400 Sierra Point Parkway Brisbane 94005 CA
Company Phone Number: 822-5500 Stock Exchange / Ticker: NASDAQ ANNX
|
1.82%